AbCellera Biologics Inc (id:7592 ABCL)
2.76 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 2:28:55 PM)
Exchange closed, opens in 1 day 19 hours
About AbCellera Biologics Inc
Market Capitalization 782.72M
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
| Headquarters (address) |
2215 Yukon Street Vancouver V5Y 0A1 BC Canada |
| Phone | 604 559 9005 |
| Website | https://www.abcellera.com |
| Employees | 586 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | ABCL |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 2.34 - 6.06 |
| Market Capitalization | 782.72M |
| P/E trailing | -5.41 |
| P/E forward | -4.02 |
| Price/Sale | 23.75 |
| Price/Book | 0.725 |
| Beta | 0.351 |
| EPS | -0.610 |
| EPS Canada (ID:82, base:722) | 1.84 |